WO2010139981A3 - Processes for preparing crystalline forms of dasatinib - Google Patents

Processes for preparing crystalline forms of dasatinib Download PDF

Info

Publication number
WO2010139981A3
WO2010139981A3 PCT/GB2010/050894 GB2010050894W WO2010139981A3 WO 2010139981 A3 WO2010139981 A3 WO 2010139981A3 GB 2010050894 W GB2010050894 W GB 2010050894W WO 2010139981 A3 WO2010139981 A3 WO 2010139981A3
Authority
WO
WIPO (PCT)
Prior art keywords
dasatinib
processes
crystalline forms
preparing crystalline
polymorphs
Prior art date
Application number
PCT/GB2010/050894
Other languages
French (fr)
Other versions
WO2010139981A2 (en
Inventor
Vinayak Govind Gore
Laxmikant Patkar
Amit Bagul
Priyesh Surendra Vijaykar
Mahesh Edake
Original Assignee
Generics [Uk] Limited
Mylan India Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics [Uk] Limited, Mylan India Private Limited filed Critical Generics [Uk] Limited
Publication of WO2010139981A2 publication Critical patent/WO2010139981A2/en
Publication of WO2010139981A3 publication Critical patent/WO2010139981A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to processes for the preparation of dasatinib and to crystalline monohydrate and anhydrous polymorphic forms of dasatinib. The invention further relates to pure polymorphs, to pharmaceutical compositions comprising said polymorphs and to uses thereof.
PCT/GB2010/050894 2009-06-03 2010-05-28 Processes for preparing crystalline forms WO2010139981A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN828/KOL/2009 2009-06-03
IN828KO2009 2009-06-03

Publications (2)

Publication Number Publication Date
WO2010139981A2 WO2010139981A2 (en) 2010-12-09
WO2010139981A3 true WO2010139981A3 (en) 2011-05-05

Family

ID=42754463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/050894 WO2010139981A2 (en) 2009-06-03 2010-05-28 Processes for preparing crystalline forms

Country Status (1)

Country Link
WO (1) WO2010139981A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101891738B (en) * 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 Dasatinib polymorph and preparation method and medical composition thereof
CN102898424A (en) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 Novel polymorphs of dasatinib, and preparation method thereof
CN102408423B (en) * 2011-11-29 2013-12-25 上海希迪制药有限公司 Method for preparing large particle size dasatinib
WO2013078973A1 (en) * 2011-11-29 2013-06-06 上海创诺制药有限公司 Large particle diameter dasatinib and preparation and use thereof
NZ630288A (en) * 2012-04-20 2015-08-28 Shilpa Medicare Ltd Process for preparing dasatinib monohydrate
CZ306598B6 (en) * 2012-12-06 2017-03-22 Zentiva, K.S. A method of preparation and purification of new and known polymorphs and dasatinib solvates
WO2017002131A1 (en) * 2015-06-29 2017-01-05 Msn Laboratories Private Limited Crystalline forms of n-(2-chloro-6-methy]phenvn-2-[f6-[4-(2-hvdroxvethvl)-l- piperazinvil-2-methvl-4-pvrimidinvllaminol-5-thiazolecarboxamide and their process thereof
US9168226B1 (en) 2015-08-07 2015-10-27 David Wong Injectable particle
CN107519175A (en) * 2016-06-21 2017-12-29 上海方予健康医药科技有限公司 A kind of pyrimidine compound or its salt are preparing the application in being used to prevent and/or treat the medicine of the disease related to FLT3 or obstacle
US10800771B2 (en) 2016-12-01 2020-10-13 Natco Pharma Limited Process for the preparation of dasatinib polymorph
CN108239086B (en) * 2016-12-27 2023-06-16 四川科伦药物研究院有限公司 Preparation method of dasatinib N-6 anhydrous crystal
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
TWI770624B (en) 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 Use of nilotinib lauryl sulfate salt dosage form for treating chronic myeloid leukemia
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
GB2592680A (en) * 2020-03-06 2021-09-08 Zentiva Ks Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof
CN113024536B (en) * 2021-03-12 2022-05-27 湖南师范大学 5-aminothiazole methanamide compound containing pyrimidine-piperazine ring and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261305A1 (en) * 1999-04-15 2005-11-24 Jagabandhu Das Cyclic protein tyrosine kinase inhibitors
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261305A1 (en) * 1999-04-15 2005-11-24 Jagabandhu Das Cyclic protein tyrosine kinase inhibitors
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof

Also Published As

Publication number Publication date
WO2010139981A2 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2009006590A3 (en) Docetaxel process and polymorphs
WO2010067374A3 (en) Polymorphs of dasatinib
WO2010139979A3 (en) Processes for preparing crystalline forms of dasatinib
WO2010092090A3 (en) Novel salts of sitagliptin
WO2009104021A3 (en) Novel polymorphs and processes for their preparation
WO2010014883A3 (en) Azacitidine process and polymorphs
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
WO2011024192A3 (en) Novel polymorphs of raltegravir
WO2010049449A3 (en) Novel salts of sunitinib
WO2010129636A3 (en) Lenalidomide polymorph
EP3020704A3 (en) Crystalline polymorphs of clevidipine butyrate
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2011023954A3 (en) Polymorphic forms of manidipine
WO2009062659A3 (en) Polymorphs of enantiopure erdosteine
WO2010061220A3 (en) Novel processes and pure polymorphs
WO2011045774A3 (en) Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
WO2011058524A3 (en) Crystalline forms of bosentan salts and processes for their preparation
WO2010119450A3 (en) An improved process for the preparation of desmopressin or its pharmaceutically acceptable salts
WO2010146595A3 (en) Novel polymorphs of flibanserin hydrochloride
WO2011095985A3 (en) Rasagiline salts and processes for the preparation thereof
WO2010122575A3 (en) Process for the preparation of pure paliperidone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10722402

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10722402

Country of ref document: EP

Kind code of ref document: A2